Clinical Trial: Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07142044) titled 'Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)' on Aug. 19.

Brief Summary: The goal of this clinical trial is to learn if the oral drug candidate EC5026 is safe and targets the correct pathways to treat Parkinson's Disease in adults. It will also learn about the levels of drug that are achieved in blood and in the fluid surrounding the brain (spinal fluid). The main questions it aims to answer are:

* Is EC5026 safe in adults with Parkinson's Disease?

* What are the levels of EC5026 achieved after oral administration for 28 days?

* What molecules or pathways does EC5026 target, and to w...